# perceptive™

Your Trusted Imaging Partner for Alzheimer's Disease Research

With nearly 30 years of neuroimaging experience in Alzheimer's disease (AD), Perceptive is the imaging partner you can rely on for end-to-end solutions that span the drug development lifecycle.

Specializing in PET and MRI imaging biomarkers, Perceptive delivers preclinical discovery through scalable late-phase global trial services with a unified operational and scientific framework.

▶ **750+** CNS trials supported   ▶ **260+** AD trials supported   ▶ **18** AD diagnostic and therapeutic approvals supported   ▶ **800+** Neurodegenerative preclinical studies

Scientific and Medical Leadership

Perceptive supports your AD studies with industry-recognized scientific expertise. Our team brings an unmatched depth of expertise in CNS imaging science, led by globally recognized scientific and medical experts who are advancing the field through innovation and collaboration.

Translational Biomarker Strategy

Perceptive provides expert guidance and infrastructure to translate imaging science into actionable biomarkers for early clinical decision-making, including:

▶ Preclinical and translational study design

▶ In-house clinic for first-in-human studies in London, UK

▶ Imaging biomarkers for target engagement, dose selection, and PD response

▶ PET/MRI analytics tailored to CNS drug development

Proven Late-phase CNS Trial Imaging Execution

With a scalable infrastructure including centralized tracer supply, Perceptive is a trusted partner for your complex, pivotal trials. Our technology and processes are harmonized across our global locations, enabling round-the-clock image receipt, processing, query management, and reads, ensuring faster TATs and reduced backlogs to help you meet trial timelines with confidence.

Advanced Imaging Analytics and AI/ML

▶ Automated pipelines and machine learning tools that deliver precision, scalability, and reproducibility in CNS trials.

▶ Validated and exploratory MRI pipelines, incl. advanced MRI modalities

▶ Advanced analytical pipelines with greater statistical power than standard SUV methods: IQ Platform

Meet Our Alzheimer's Scientific Leadership

Rohit Sood, MD, PhD
VP, Scientific & Medical Services

David Cash, PhD
Sr. Medical Director

David Russell, MD, PhD
Sr. Director, Clinical Research,
Scientific & Medical Services

Elif Sikoglu, PhD
Sr. Scientific Director

Sam Lockhart, PhD
Sr. Scientific Director

Ilan Rabiner, MBBCh
Head of Translational
Applications

Lisa Wells, PhD
VP, Translational Pharmacology

Phillip Kuo, MD, PhD, FACP
Consultant

Fully Validated, Advanced & Updated Quantitative Image Analysis Pipelines

▶ **Validated:** CFR 21-part 11 compliance for reliable capture of data for submission to regulatory bodies (e.g. SUVR Tau & Amyloid, Centiloid, Brain atrophy and diffusion metrics, etc.).

▶ **Harmonized:** site-specific protocols to improve data consistency, quantification, and visual interpretation across varied sites and scanners.

▶ **Customized:** pipelines can incorporate multiple MRI timepoints, differing atlases (Hammers, AAL, custom atlases), image spaces, target regions, etc.

▶ **Specialized:** BRAAK, Jack Meta, and other meaningful composite regions available.

▶ **Exploratory:** More advanced approaches with MRI modalities as well as novel tracers.

How Can We Help?

Reach out to learn how Perceptive can can help your
Alzheimer's Disease research succeed:

▶ **hello@perceptive.com**

perceptive™